NCT02073929

LIPT - Liraglutide in Polycystic Ovary Syndrome

A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Jens Faber · Academic / Other
• Sex: Female
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease. The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS. 70 women will be included in af RCT. Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.

Conditions

• Polycystic Ovary Syndrome
• Cardiovascular Disease

Interventions

Type	Name	Description
DRUG	Liraglutide for 26 weeks	GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
DRUG	placebo	Placebo s.c. daily for 26 weeks

Timeline

• Start date: 2014-03-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2014-02-28
• Last updated: 2019-02-28
• Results posted: 2019-02-28

Locations

3 sites across 1 country: Denmark